The trajectory of Viagra presents a complex case for investors in the medicinal sector. While initially a phenomenal success, producing vast sums, the patent lapse and the subsequent arrival of cheaper alternatives have drastically affected earnings. This poses questions about the future profitability of similar drug projects and suggests that simp